{"id":8220,"date":"2025-08-03T09:03:41","date_gmt":"2025-08-03T06:03:41","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8220"},"modified":"2025-08-03T09:03:41","modified_gmt":"2025-08-03T06:03:41","slug":"the-most-anticipated-trials-at-esc-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/the-most-anticipated-trials-at-esc-2025\/","title":{"rendered":"\u201cThe Most Anticipated Trials at ESC 2025\u201d"},"content":{"rendered":"
\u201cThe Most Anticipated Trials at ESC 2025\u201d<\/div>\n
<\/div>\n
Summary:<\/div>\n
<\/div>\n
1. ESC Congress 2025 Overview<\/span><\/div>\n
\u2022 ESC 2025 will be held in Madrid, Spain (Aug 29 \u2013 Sept 1).<\/span><\/div>\n
\u2022 Features 38 sessions, including 10 Hot Line and 28 late-breaking science sessions.<\/span><\/div>\n
\u2022 Focus: New treatments, global health issues, and redefining guidelines.<\/span><\/div>\n
2. Focus on Long-Term Therapy Reassessment<\/span><\/div>\n
\u2022 REBOOT-CNIC & BETAMI-DANBLOCK:<\/span><\/div>\n
Reevaluate long-term beta-blockers after heart attack, especially in patients with preserved ejection fraction.<\/div>\n
\u2022 Goal: Reduce drug burden and costs.<\/span><\/div>\n
3. Antiplatelet\/Anticoagulant Simplification<\/span><\/div>\n
\u2022 Trials: NEO-MINDSET, TARGET FIRST, DUAL-ACS, ALONE-AF<\/span><\/div>\n
\u2022 Explore early withdrawal of aspirin or OACs to reduce bleeding and simplify care.<\/span><\/div>\n
4. Global Health Highlight: Chagas Cardiomyopathy<\/span><\/div>\n
\u2022 PARACHUTE-HF Trial:<\/span><\/div>\n
Tests sacubitril\/valsartan vs enalapril in Latin American patients.<\/div>\n
\u2022 May lead to first guideline-based treatment for this neglected disease.<\/span><\/div>\n
5. New Hypertension Therapies<\/span><\/div>\n
\u2022 BaxHTN: Tests new aldosterone synthase inhibitor.<\/span><\/div>\n
\u2022 KARDIA-3: Tests zilebesiran, a twice-yearly siRNA therapy for BP control.<\/span><\/div>\n
\u2022 siRNA could revolutionize hypertension treatment adherence.<\/span><\/div>\n
6. Heart Failure Breakthroughs<\/span><\/div>\n
\u2022 DAPA ACT HF-TIMI 68:<\/span><\/div>\n
Starts SGLT2 inhibitors during hospitalization for acute HF.<\/div>\n
\u2022 VICTOR\/VICTORIA: Tests vericiguat as a daily option for chronic HF.<\/span><\/div>\n
7. Hypertrophic Cardiomyopathy (HCM)<\/span><\/div>\n
\u2022 ODYSSEY-HCM & MAPLE-HCM:<\/span><\/div>\n
May shift treatment toward oral myosin inhibitors (mavacamten, aficamten), reducing need for surgery.<\/div>\n
<\/div>\n
\u2e3b<\/div>\n
<\/div>\n
\ud83d\udccc Quote from Prof. Tomasz Guzik:<\/div>\n
<\/div>\n
\u201cThese trials may change daily practice and guidelines \u2014 from how we treat heart attacks to managing hypertension and rare heart diseases.\u201d<\/div>\n
https:\/\/www.escardio.org\/The-ESC\/Press-Office\/Press-releases\/What-are-the-most-anticipated-trials-at-ESC-Congress-2025<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

\u201cThe Most Anticipated Trials at ESC 2025\u201d Summary: 1. ESC Congress 2025 Overview \u2022 ESC 2025 will be held in Madrid, Spain (Aug 29 \u2013 Sept 1). \u2022 Features 38 sessions, including 10 Hot Line and 28 late-breaking science sessions. \u2022 Focus: New treatments, global health issues, and redefining guidelines. 2. Focus on Long-Term Therapy […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8220","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8220"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8220\/revisions"}],"predecessor-version":[{"id":8221,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8220\/revisions\/8221"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}